HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor.

Abstract
A combination of paclitaxel (Taxol) and mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK/Erk) inhibitor represents a rational new approach to chemotherapy. We performed Affymetrix microarray analysis to understand the global effects of this combination in lung carcinoma. Genes involved in cell cycle control, apoptosis, adhesion, proliferation, invasion, and metastasis were modulated. We observed similar patterns of gene modulation in ovarian and melanoma cell lines, indicating the general applicability of these findings. Functional genomic analysis identified two genes as new targets of drug-induced tumor apoptosis. The MGSA/Gro1 gene, important in melanoma growth, was induced by paclitaxel and reduced by MEK inhibition. Blockage of paclitaxel-induced melanoma growth stimulatory activity significantly reduced melanoma growth. Additionally, the expression of topoisomerase III beta, which exhibited a clear pattern of gene reduction by a combination of the two drugs, was significantly increased (5.7-fold) in primary lung cancers but not adjacent tissues. These findings provide potential new biomarkers and gene targets for the development of improved cancer treatment.
AuthorsDebra J Taxman, Jeffrey P MacKeigan, Casey Clements, Daniel T Bergstralh, Jenny P-Y Ting
JournalCancer research (Cancer Res) Vol. 63 Issue 16 Pg. 5095-104 (Aug 15 2003) ISSN: 0008-5472 [Print] United States
PMID12941840 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Butadienes
  • CXCL1 protein, human
  • Chemokine CXCL1
  • Chemokines
  • Chemokines, CXC
  • Chemotactic Factors
  • Enzyme Inhibitors
  • Intercellular Signaling Peptides and Proteins
  • Nitriles
  • U 0126
  • Dactinomycin
  • Mitogen-Activated Protein Kinase Kinases
  • Paclitaxel
Topics
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Apoptosis (drug effects)
  • Butadienes (administration & dosage)
  • Chemokine CXCL1
  • Chemokines (biosynthesis)
  • Chemokines, CXC
  • Chemotactic Factors (biosynthesis)
  • Dactinomycin (pharmacology)
  • Enzyme Inhibitors (administration & dosage)
  • Female
  • Gene Expression Profiling
  • Humans
  • Intercellular Signaling Peptides and Proteins (biosynthesis)
  • Lung Neoplasms (drug therapy, genetics, pathology)
  • Melanoma (genetics)
  • Mitogen-Activated Protein Kinase Kinases (antagonists & inhibitors)
  • Nitriles (administration & dosage)
  • Oligonucleotide Array Sequence Analysis
  • Ovarian Neoplasms (genetics)
  • Paclitaxel (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: